Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
HUTCHMED announced a licensing and co-development deal with GSK for a novel KRAS-EGFR antibody conjugate. The agreement includes $1.3 billion in potential value, with HUTCHMED leading phase I trials and GSK taking over ex-China development.
Hutchmed announced a licensing and co-development agreement with GSK for HMPL-A830, a novel KRAS-EGFR antibody conjugate, valued at $1.3 billion with milestone and royalty potential. Deal aims to accelerate global development and validate ATTC platform.